Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. - Wikidata - awgldk - TriplyDB

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.

http://www.wikidata.org/entity/Q37392967

about

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

P2860

Q58714240-2F915923-AE79-43D5-A237-48BEE61B378F

P2860

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.

http://www.wikidata.org/entity/Q37392967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@en

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@nl

type

label

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@en

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@nl

prefLabel

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@en

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@nl

P1433

Q37392967-B22CB22C-9C7D-4B0D-8578-618CDEE48193

P1476

Q37392967-C5ACB24A-9DE1-43DC-966F-6A4AF424B04A

P2093

Q37392967-0A1767DE-8E5F-45D0-998C-0FD52A5C958B

Q37392967-3646D2A2-87AF-4EB5-A00F-9B45A00BAB87

Q37392967-4D24B7C9-0D77-4F1C-8FD2-668C9BFB512F

Q37392967-AF389EAB-FA76-4B1C-8645-0823A9FCB002

Q37392967-B1339E61-BFA2-4778-B399-70F90058824E

Q37392967-CB87DDCE-F85B-4662-AA84-D94915DEE61A

Q37392967-CD2E89BB-3E05-45C0-A490-3DB4568C0F1A

Q37392967-DC8727E6-C13C-4852-AD80-A7AF55CFBD7F

Q37392967-E588B1BA-74B0-4474-8BCE-8F84C1E0CDDC

Q37392967-EDE8B491-6117-4DD1-910B-441D4D2C6370

P2860

Q37392967-12B76E50-3A4E-4719-876A-0D4D56ED1F70

Q37392967-561E2259-031D-4C04-97B2-EEED7C8297B0

Q37392967-6B1A93C5-B3ED-4928-A31C-3E10BCD3CE4D

Q37392967-7FA45F32-C954-4987-BEED-86E3ADBF005E

Q37392967-908D5295-9AEB-4AB4-811A-BDF21B73BE1D

Q37392967-91C0E7C3-0909-4639-A8A8-1D14F6656DE4

Q37392967-C51F4574-53EE-4B7E-B721-2F448D07A46B

Q37392967-C6E5BD7E-88C6-4E84-8458-81CBD1570929

Q37392967-DF74AC27-14D9-4675-90F5-65F50FD96F8D

Q37392967-E624BD93-BF67-4D45-B70B-5352A6A0395C

P304

Q37392967-6CF14386-22D7-48C2-BD8C-D863339627DD

P31

Q37392967-AE6146AC-DE9E-4A4F-8589-C0DD9CA93978

P356

Q37392967-A3EC7A15-0F26-4464-8C8D-B867A8EC987A

P407

Q37392967-36D9591F-A5F7-4225-B76D-E6B419B11CF2

P433

Q37392967-512571EC-7D6F-4B8E-A17E-C584A927B222

P478

Q37392967-F17F9B01-C470-46E9-AC6F-AE7DB478C8A3

P577

Q37392967-6C7405D6-3E6B-4762-937F-9EDD07BF9F65

P698

Q37392967-E12414F2-E2A6-4A2E-ABE2-07DC74D8CEFB

P921

Q37392967-A10F8B3F-BE32-4C8B-A3E0-574303AFEA5B

P932

Q37392967-7AB41E5E-A2A9-4459-BC75-6BED27EA784D

P356

ONCOTARGET.8934

P1433

P1476

Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.

@en

P2093

Alexis Ambrun

http://www.w3.org/2001/XMLSchema#string

Alpha Diallo

http://www.w3.org/2001/XMLSchema#string

Antoine Ramade

http://www.w3.org/2001/XMLSchema#string

Clara Fontaine-Delaruelle

http://www.w3.org/2001/XMLSchema#string

Clémentine Daveau

http://www.w3.org/2001/XMLSchema#string

Eve-Marie Neidhardt

http://www.w3.org/2001/XMLSchema#string

Julien Péron

http://www.w3.org/2001/XMLSchema#string

Jérôme Fayette

http://www.w3.org/2001/XMLSchema#string

Marc Poupart

http://www.w3.org/2001/XMLSchema#string

Philippe Céruse

http://www.w3.org/2001/XMLSchema#string

P2860

Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.

P304

37297-37304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8934

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27119503

http://www.w3.org/2001/XMLSchema#string

P921

head and neck squamous cell carcinoma

P932

5095077

http://www.w3.org/2001/XMLSchema#string